Pros and cons of treating murine myasthenia gravis with anti-C1q antibody

Keyphrases

• Myasthenia Gravis 100%
• Anti-C1q 100%
• Anti-C1q Antibodies 100%
• Experimental Autoimmune Myasthenia Gravis 66%
• Kidney 33%
• B Cells 33%
• Interleukin-6 33%
• Immune Complex 33%
• Cellular Level 33%
• C57BL 33%
• T Cell Subpopulations 33%
• Lymph Node 33%
• Treatment Efficacy 33%
• Clinical Severity 33%
• Acetylcholine Receptor Antibody 33%
• Lymph Node Cells 33%
• Classical Complement Pathway 33%
• Production Cell 33%

INIS

• antibodies 100%
• lymph nodes 100%
• administration 50%
• production 50%
• mice 50%
• kidneys 50%
• populations 50%
• levels 50%
• receptors 50%
• acetylcholine 50%
• side effects 50%
• complement 50%
• deposits 50%
• boron 6 50%

Immunology and Microbiology

• Myasthenia gravis 100%
• Complement Component C1q 100%
• Complement Component C1q Antibody 100%
• Experimental Autoimmune Myasthenia Gravis 66%
• T Cell 33%
• Kidney 33%
• B Cell 33%
• Mouse 33%
• Interleukin-6 33%
• Immune Complex 33%
• Cell Population 33%
• Lymph Node 33%
• Isotype 33%
• Cell Level 33%
• Cholinergic Receptor Antibody 33%
• Lymph Node Cell 33%
• Classical Complement Pathway 33%